<abstract xmlns="http://www.w3.org/1999/xhtml">A 65-year-old woman was found to have severe autoimmune hemolytic anemia. The patient was group A1 Rh0(D) positive. The direct antiglobulin test was strongly positive with anti-C3 and negative with anti- IgG. The serum contained two distinct IgM antibodies, auto-anti-I and auto-anti-AI. Both were reactive at 22 °C. However, the anti-AI also was reactive in saline and in albumin at 37°C. An eluate revealed anti-AI and a weak anti-L Sequential 5’Chromium survival studies were done with group OI and Al red cells. The group OI red cells survived normally (97% at 24 hours) while the group A J red cells were removed in a “two- component” pattern characteristic of IgM complementfixing antibodies (62% survival at one hour, 49% at 24 hours). Based on these observations, the patient was subsequently transfused without incidence with six group O units of washed red cells prior to splenectomy. Although auto-anti-AI has been previously reported, this is the first case to demonstrate the use of 51Cr survival studies to determine its clinical significance.</abstract>

A 65-year-old woman was found to have severe autoimmune hemolytic anemia. The patient was group A1 Rh0(D) positive. The direct antiglobulin test was strongly positive with anti-C3 and negative with anti- IgG. The serum contained two distinct IgM antibodies, auto-anti-I and auto-anti-AI. Both were reactive at 22 °C. However, the anti-AI also was reactive in saline and in albumin at 37°C. An eluate revealed anti-AI and a weak anti-L Sequential 5’Chromium survival studies were done with group OI and Al red cells. The group OI red cells survived normally (97% at 24 hours) while the group A J red cells were removed in a “two- component” pattern characteristic of IgM complementfixing antibodies (62% survival at one hour, 49% at 24 hours). Based on these observations, the patient was subsequently transfused without incidence with six group O units of washed red cells prior to splenectomy. Although auto-anti-AI has been previously reported, this is the first case to demonstrate the use of 51Cr survival studies to determine its clinical significance.

Cold Autoimmune Hemolytic Anemia with Auto-Anti-Ai Specificity: 51Chromium Survival Studies

Immunohematology

Cold Autoimmune Hemolytic Anemia with Auto-Anti-Ai Specificity: Chromium Survival Studies

A 65-year-old woman was found to have severe autoimmune hemolytic anemia. The patient was group A1 Rh0(D) positive. The direct antiglobulin test was strongly...

Cold Autoimmune Hemolytic Anemia with Auto-Anti-Ai Specificity: ⁵¹Chromium Survival Studies

Data publikacji: 31 gru 2020

Zakres stron: 17 - 20

DOI: https://doi.org/10.21307/immunohematology-2019-1124

© 1987 Mary H. McGinniss et al., published by Sciendo.